Detection of rs12979860 IL28B Polymorphisms Involved in Response to Chronic Hepatitis C Treatment

Abolfazl Fateh1, Mohammad Reza Aghasadeghi2, Hossein Keyvani3, Hamid Reza Mollaie3, Shamsi Yari4, Ali Reza Hadizade Tasbiti4, Morteza Ghazanfari4, Seyed Hamid Reza Monavari3*

Abstract

Background: A recent genome-wide association study (GWAS) on patients with chronic hepatitis C (CHC) treated with peginterferon and ribavirin (pegIFN-α/RBV) identified a single nucleotide polymorphism (SNP) on chromosome 19 (rs12979860) which was strongly associated with a sustained virological response (SVR). The aim of this study was twofold: to study the relationship between IL28B rs12979860 and sustained virological response (SVR) to pegIFN-α/RVB therapy among CHC patients and to detect the rs12979860 polymorphism by high resolution melting curve (HRM) assay as a simple, fast, sensitive, and inexpensive method. Materials and Methods: The study examined outcomes in 100 patients with chronic hepatitis C in 2 provinces of Iran from December 2011 to June 2013. Two methods were applied to detect IL28B polymorphisms: PCR-sequencing as a gold standard method and HRM as a simple, fast, sensitive, and inexpensive method. Results: The frequencies of IL28B rs12979860 CC, CT, and TT alleles in chronic hepatitis C genotype 1a patients were 10% (10/100), 35% (35/100), and 6% (6/100) and in genotype 3a were 13% (13/100), 31% (31/100), and 5% (5/100), respectively. In genotype 3a infected patients, rs12979860 (CC and CT alleles) and in genotype 1a infected patients (CC allele) were significantly associated with a sustained virological response (SVR). The SVR rates for CC, CT and TT (IL28B rs12979860) were 18%, 34% and 4%, respectively. Multiple logistic regression analysis identified two independent factors that were significantly associated with SVR: IL-28B genotype (rs 12979860 CC vs TT and CT; odds ratio [ORs], 7.86 and 4.084, respectively), and HCV subtype 1a (OR, 7.46). In the present study, an association between SVR rates and IL28B polymorphisms was observed. Conclusions: The HRM assay described herein is rapid, inexpensive, sensitive and accurate for detecting rs12979860 alleles in CHC patients. This method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be clinically beneficial in predicting treatment response in HCV genotype 1 and 3 infected patients. In addition, it was demonstrated that CC and CT alleles in HCV-3a and the CC allele in HCV-1a were significantly associated with response to pegIFN-α/RBV treatment. The present results may help identify subjects for whom the therapy might be successful.

Keywords: Chronic hepatitis C - single nucleotide polymorphism - sustained virological response

Introduction

Hepatitis C virus (HCV) is an important public health problem worldwide that causes acute and chronic liver diseases like cancer. Approximately 80% of subjects with acute hepatitis C progress into a chronic disease. Chronic hepatitis C virus (CHC) infection is an important cause for developing (10-20%) cirrhosis and hepatocellular carcinoma (HCC) that often results in liver failure and thus in liver transplantation (Keyvani et al., 2012). HCC is the seventh most common cancer worldwide and the third most common cause of cancer mortality (Yang and Roberts., 2010). HCC usually expands in patients infected with chronic hepatitis B (HBV) or chronic hepatitis C (CHC). HBV vaccination programs among general population in high risk areas and using antiviral treatment in chronic hepatitis C and B, could be prevented liver cancer (Su et al., 2013). In Iran, incidence of hepatocellular carcinoma is low because most cases are due to HBV and this infection was less common (Pourhoseingholi et al., 2010).

Although successful execution of direct-acting
Antiviral therapy was recently demonstrated in Western countries, combination pegylated interferon-alpha (pegIFN-α) plus ribavirin (RBV) (pegIFN-α/RBV) is still the most effective treatment for patients with CHC in central Asia (Beinhardt et al., 2013; Ghany et al., 2009). Standard of care (SOC) for treatment of CHC infection is pegIFN-α/RBV, that leads to sustained virological response (SVR) in about 40%-60% of subjects with CHC genotype 1 (HCV-1) and 80% or more in those with genotypes 2 and 3 of this infection (Tsibota et al., 2011). Higher SVR rates have been obtained in subjects infected with other HCV genotypes (Ge et al., 2009; Antaki et al., 2010; Tsibota et al., 2011; European Association for the Study of the Liver., 2014) and middle SVR rates have been obtained in those with HCV genotype 4 (Antaki et al., 2010). Interestingly, Iranian patients with CHC respond better to SOC treatment (Alavian et al., 2010). Of the various host (age, sex, body mass index, race, usage immunosuppressive drugs, host genetic, sex, stage of fibrosis, coinfection with other hepatitis viruses and human immunodeficiency virus) and viral factors (HCV genotype, HCV viral load) associated with the effectiveness of pegIFN-α/RBV therapy (European Association for the Study of the Liver., 2014).

A recent genome-wide association study (GWAS) on patients with CHC treated with pegIFN-α/RBV identified a single nucleotide polymorphism (SNP) on chromosome 19 (rs12979860 and rs8099917) that was strongly associated with sustained virological response (SVR). The CC alleles (rs12979860) and TT alleles (rs8099917) were associated with SVR compared with the TT (rs12979860) and GG (rs8099917) alleles which increasing the possibility that the C allele may favour spontaneous clearance of HCV (Ge et al., 2009). There are different opinions for clinical determination of IL28B testing; but, it seems that it can help in decision-making with regard to treatment (Grebelly et al., 2010). IL28B are the robust pretreatment prognosticator of SVR to pegIFN-α/RBV and protease inhibitor triple therapy in patients with HCV-1 infection. Testing may be considered when the patient or provider wants additional information on the probability of treatment response or the probable duration of the needed treatment (Class 2a, Level B) (Ghany et al., 2011).

Several methods, such as direct DNA sequencing, real-time PCR, amplification refractory mutation system polymerase chain reaction (ARMS-PCR), polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and allele-specific PCR can be used for genotyping SNPs, such as IL28B alleles (Chen et al., 2003). The aim of this study was twofold: to study the relationship between IL28B rs12979860 and SVR to pegIFN-α/RBV therapy among CHC patients and to detecting rs12979860 polymorphism by High Resolution Melting Curve (HRM) as a simple, fast, sensitive, and inexpensive method.

**Materials and Methods**

**Patients**

One hundred (n=100) patients with chronic hepatitis C in 2 provinces of Iran (Digestive Disease Research Center of Tehran and Virology Laboratory of the Besat Specialist Clinic of Kerman, IRAN from) from December 2011 to June 2013 enrolled this study. The exclusion criteria included having other hepatitis virus (hepatitis B and D viruses), using immunosuppressive drugs (organ transplantation), diabetes mellitus, coexistent autoimmune liver diseases and having any of the various diseases that suppress the immune system (human immunodeficiency virus).

**Treatment of patients**

One hundred patients were treated with 180 milligram per week (mg/week) of Pegylated interferon alfa-2a (Peg-IFNα-2a) and 1000-1200 milligram per day (mg/day) of ribavirin (RBV). The patients with chronic HCV genotypes 1a and 3 were treated for 48 and 24 weeks, respectively (Alavian et al., 2010). To determine the end of the treatment, the viral load (HCV RNA) in blood was measured at the end of the treatment and 6 months later. The absence of detectable RNA of HCV in blood for at least 24 weeks after discontinuing treatment was defined as a Sustained Virologic Response (SVR) (Figure 1).

**Sample collection**

About 8 mL blood samples from HCV patients were collected in Ethylenediaminetetraacetic acid (EDTA) tubes. Plasma was separated and aliquoted. Then, it was stored at -80°C until analysis. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll (Ficoll-Paque PLUS, GE Healthcare) and stored at -20°C.

**Virologic testing**

HCV genotyping and HCV viral loading from plasma samples were carried out using the AmpliSens® HCV-1/2/3-FEP PCR kit and AmpliSens® HCV-Monitor-FRT Real-Time PCR kit (InterLabService Ltd., Moscow) according to the manufacturer’s instructions, respectively.

**Laboratory procedures**

Liver enzyme function tests were carried out for all the patients. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and alkaline phosphatase (ALP) were measured on the Selectra E Clinical Chemistry analyzer (Vital Scientific, The Netherlands).
Detection of rs12979860 IL28B Polymorphisms Involved in Response to Chronic Hepatitis C Treatment

PBMC samples using HRM assay. Primer sequences were used for amplifications as follows: forward primer: 5’-CCTGGACGTGGATGGGTA-3’ and reverse primer: 5’-GCGCGGAGTGCAATTCCA-3’.

The real-time PCR (20 μl) was composed of 10 μl of 2×AccuMelt HRM SuperMix (Quanta BioSciences, Inc, USA), forward and reverse primers (0.25 μl of each primer was used), nuclease-free water (4.5 μl), and DNA extracted from PBMCs (5 μl). The reactions were set up in triplicate in a 96-well PCR plate and processed on a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc). CFX Manager Software Version 3.0 (Bio-Rad Laboratories, Inc) was applied to set up the sample arrangement on the PCR plate, to define PCR conditions, to monitor the amplification in real time, to view melting curves, and to calculate DNA concentrations and other PCR parameters.

The amplification reaction mixture consisted of 30 ng of genomic DNA; the cycling parameters of PCR were as follows: 95°C for 5 min followed by 45 cycles of 95°C for 10s, 60°C for 30 s, and 60°C for 30 s. Then, high-resolution melt curves analysis was carried out by fluorescence acquisition during a temperature increase from 60°C to 95°C, using increments of 0.1°C with holding steps of 10 s (Figure 2).

**PCR Sequencing**

To confirm the HRM method, the HRM genotyping results of rs12979860 should be 100% compatible with the DNA sequencing consequences. The primers for PCR and sequencing reactions were as follows: forward primer: 5’-CTCTGCACAGTCTGGGATTCCT-3’ and reverse primer: 5’-CTGAGGGACCGCTACGTAAGTC-3’.

The amplification reaction mixture consisted of 50ng of genomic DNA, forwards and reverse primers (0.15 µM of each), different deoxynucleotides (0.2 mM of each), Ex Taq DNA Polymerase (1.5U) (Takara, Korea Biomedical, Inc), and PCR buffer (10X) containing 1.5 mM MgCl₂. First, the PCR was performed by denaturing the samples (for 10 min at 95°C); then, 35 cycles including 95°C for 45 s, 66°C for 45 s, 72°C for 45s, and a final extension at 72°C for 10 min were followed. Electrophoresis of the PCR products were carried out on the agarose gels (1%). PCR products (390 bp) were purified by High Pure PCR Product Purification Kit (Roche, Germany) then, three IL28B 12979860 genotypes (TT, CT and CC) were analyzed by direct sequencing (Figure 3).

**Statistical analysis**

All the calculations were performed using SPSS version 21 software (SPSS, Inc., Chicago, IL). Predictors for SVR were evaluated by multivariate logistic regression analysis. Multivariate analysis included all significant parameters from univariate analysis as well as the parameters that were available from all patients. Analysis of continuous variables was performed using independent-samples t-test and Kruskal-Wallis test. χ² and Fisher’s exact tests were used for comparing frequency data and evaluating the relationships between groups. Differences with the p-value of >0.05 were considered statistically significant.

**Ethics statement**

The current study was approved by Ethical Committee of School of Public Health, Tehran University of Medical Sciences. An informed consent was also directly obtained from each patient.

**Results**

**Patient characteristics**

One hundred patients (n=100) with chronic HCV infection were followed up in this study. There were 51 patients (n=51) with HCV genotype 1a and 49 patients (n=49) with HCV genotype 3a infection. Mean age of the patients (84 males and 16 females) was 52.2±4.6
Abolfazl Fateh et al
Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

(ranging from 41 to 61 years old). Pretreatment clinical and virological characterizations including alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALKP), HCV genotype, and HCV viral load are showed in Table 1. There were no significant differences between HCV genotypes and age, ALT, AST, and ALKP levels, whiles they were significantly different from HCV viral load (p=0.018).

The sustained virological response (SVR) rate in the patients with HCV genotype 1a and 3a infection was 18 (35.3%) and 38 (77.55%), respectively. SVR rate in HCV genotype 1a was significantly less than of the patients with HCV genotype 3a (p=0.001) (Figure 1). Among the HCV genotype 1a and HCV genotype 3a groups, 33 (64.7%) and 11 (22.45%) patients were non-responders (Non-SVR). No significant differences were found between the HCV treatment response (SVR) and age, sex, baseline liver enzymes levels (ALT, AST, and ALKP), whereas a significant relationship between SVR rate and HCV viral load was shown (p=0.041) (Table 2).

Prevalence of rs12979860 genotype according to HCV genotypes

In the current study, prevalence of rs12979860 genotypes CC, CT, and TT in HCV genotype 1a was 10 (10%), 35 (35%), and 6 (6%), respectively and in HCV genotype 3a, it was 13 (13%), 31 (31%), and 5 (5%), respectively (Table 3). No statistically significant difference was seen between rs12979860 genotype and HCV genotype (p=0.710).

Relationship between rs12979860 genotypes with Laboratory parameters

Baseline serum ALT, AST, and ALKP levels in the patients with CC genotype of rs12979860 were 248.8±245.9, 248.8±245.9, and 586.4±360.7, respectively. Among the patients with non-CC genotype, they were 256.6±215.3, 246.3±195.1, and 607.5±418.8, respectively. This difference was not statistically significant (p=0.661 vs 0.689) (Table 3).

Baseline viral load in the patients with CC genotype was less than the patients with non-CC genotype of rs12979860; but, no significant difference was found in the baseline viral load between the patients with CC genotype and non-CC genotype of rs12979860 (3.3×10^6±1.7×10^6 vs 4.6×10^6±2.5×10^6 and 4.5×10^6±2.4×10^6, respectively, p=0.127).

Sustained Virological Response Rates According to rs12979860 Genotypes

Out of 100 patients of CHC subjects, 51 patients (51%) were infected with HCV genotype 1a and 49 patients (49%) with genotype 3a. Among 51 patients with HCV genotype 1a infection, 18 (35.3%) subjects and 49 (100%) were infected with HCV genotype 3a in non-SVR subjects, the frequencies were 4, 24, and 5, respectively. CC genotype of rs12979860 was significantly associated with SVR compared to non-CC genotype (p=0.032).

For 38 patients with HCV genotype 3a infection, frequencies of rs12979860 CC, CT, and TT genotypes in SVR subjects were 6, 11, and 1, respectively, while in non-SVR subjects, the frequencies were 4, 24, and 5, respectively. CC genotype of rs12979860 was significantly associated with SVR compared to non-CC genotype (p=0.032).

| Patients Features | SVR | Non-SVR | Total | p-value |
|-------------------|-----|---------|-------|---------|
| Number of patients (%) | 56 | 44 | 100 | - |
| Age (years) | 52.3±4.4 | 52.2±5.0 | 52.2±4.6 | 0.966 |
| Gender (male/female) | 48/8 | 36/8 | 84/16 | 0.784 |
| HCV genotype 1a | 18 (35.3%) | 33 (64.7%) | 51 (100%) | <0.001a |
| HCV genotype 3a | 38 (77.5%) | 11 (22.5%) | 49 (100%) | |
| HCV viral load (IU/ml) | 3.8×10^6±2.2×10^6 | 4.9×10^6±2.5×10^6 | 4.3×10^6±2.3×10^6 | 0.041a |
| Baseline ALT (IU/L) | 243.9±248.2 | 260.2±205.2 | 252.1±226.7 | 0.236 |
| Baseline AST (IU/L) | 223.7±197.8 | 260.2±199.0 | 241.9±198.4 | 0.125 |
| Baseline ALKP (IU/L) | 602.5±402.0 | 724.8±490.9 | 663.6±446.4 | 0.27 |

*SVR, sustained virologic response; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALKP, alkaline phosphatase. *Statistically Significant

| IL28B Variable | CC | CT | TT | p-value |
|----------------|----|----|----|---------|
| HCV genotype (1a/3a) | 10/13 | 35/31 | 6/5 | 0.71 |
| Baseline viral load (IU/ml) | 3.3×10^6±1.7×10^6 | 4.6×10^6±2.5×10^6 | 4.5×10^6±2.4×10^6 | 0.127 |
| AST (IU/L) | 243.4±240.1 | 253.0±183.3 | 239.7±206.9 | 0.661 |
| ALT (IU/L) | 248.8±245.9 | 262.2±217.3 | 251.1±213.3 | 0.689 |
| ALKP (IU/L) | 586.4±360.7 | 558.7±481.6 | 656.3±356.0 | 0.569 |
| SVR | 18 | 34 | 4 | 0.032a |
| Non-SVR | 5 | 32 | 7 | 0.032a |

*SVR, sustained virologic response; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALKP, alkaline phosphatase. *Statistically Significant
were significantly associated with SVR (p=0.032).

Multiple logistic regression analysis identified two independent factors that were significantly associated with SVR: IL28B genotype (rs12979860 CC vs TT and CT; ORs, 7.86 and 4.084, respectively), and HCV subtype 1a (OR, 7.46) (multivariate regression data not shown).

**Discussion**

Many factors are important for the prediction of SVR in the patients with CHC before the initiation of antiviral therapy. These factors can assist physicians in decision-making on whether to start antiviral therapy or not and also motivate patients that might have high odds for virological response. Previous studies have shown that HCV genotype, baseline viral load, age, gender, body mass index (BMI), stage of disease, race, alanine aminotransferase (ALT) level, and host genetic polymorphisms of several genes (human leukocyte antigen, chemokines, interleukins and IFN-stimulated genes) are associated with SVR (Asselah et al., 2007; Wohnsland et al., 2007; Kau et al., 2008; Dai et al., 2009).

The recently published genome-wide association studies (GWAS) have provided insight into host genetic factors that are predictive of HCV disease progression and treatment outcome. Although several SNPs have an association with SVR and spontaneous HCV clearance, rs12979860 (CC genotype) and rs8099917 (TT genotype) have been identified by multiple groups with different patient cohorts (Melis et al., 2011).

There are different opinions for the clinical determination of IL28B testing; but, it seems that it can help in decision-making with regard to treatment (Grebely et al., 2010). IL28B alleles are the robust pretreatment prognosticator of SVR to pegIFN-α/RBV and protease inhibitor triple therapy in patients with HCV-1 infection. Testing may be considered when the patient or provider demands additional information on the probability of treatment response or the probable duration of the needed treatment (Class 2a, Level B) (Ghany et al., 2011).

The aim of this study was twofold: to study the relationship between IL28B rs12979860 and the sustained virological response to pegIFN-α/RBV therapy among CHC patients and determine rs12979860 polymorphism by HRM as a simple, fast, sensitive, inexpensive, sensitive and specific method.

Recently, several studies describing assays for IL28B detecting have been published (Falleti et al., 2011; Moghaddam et al., 2011). These were sequencing, also several non-sequencing assays such as restriction fragment length polymorphism (RFLP), TaqMan PCR, amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and allele-specific PCR. Most of them are expensive, time-consuming and they need specific probes and instruments.

Poon et al have recently reported, this method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be clinically beneficial in predicting treatment response in HCV genotype 1 infected patients, also this method was sensitive and cost-effective (Poon et al., 2012).

Out of 100 Iranian patients with chronic HCV, subtype 1a was the most common subtype (51%) followed by subtype 3a (49%). The distribution of HCV genotype in the present study was very similar to other Iranian studies (Zali et al., 2000; Samimi-Rad et al., 2004; Keyvani et al., 2007) but is different from observations in other Middle Eastern countries. As an example the overcoming HCV genotype was 1b in Turkey (Altuglu et al., 2008), 3a in Pakistan (Sajid et al., 2014) and 1b in Russia (Viazov et al., 1997). It is likely which differences in the race, routes of transmission, and different socioeconomic factors might describe this variation.

Liver enzymes (ALT, AST, and ALKP) are the key clinical appraisement for liver function, immune activation in HCV patients and SVR; but, the current study revealed no significant difference between liver enzymes levels, HCV genotype, IL28B rs12979860 polymorphism and SVR (Table 1, 3). Logistic regression analysis in the current study also demonstrated that pretreatment ALT, AST, and ALKP levels were not predictors of SVR in HCV patients. However, these results were consistent with the previous studies in that no associations were observed between these enzymes and IL28B rs12979860 polymorphism and SVR rates (Akkarathamrongsin et al., 2014; Eslam et al., 2014); in contrast, the results of the present study were consistent with a number of reports (Shi et al., 2012).

Liver enzymes levels were very important parameters for host factors that should be monitored carefully during
pegIFN-α/RBV treatment. In conclusion, virological and biochemical markers (HCV viral load and serum ALT, AST, and ALKP levels) were applied in detecting and monitoring of HCV disease (Afshar and Mollaie, 2012).

Two of the powerful SVR predictors are virus-related: HCV viral load and HCV genotype. Effect of the baseline viral load with HCV genotype and IL28B rs12979860 polymorphism on the treatment response was evaluated. It was demonstrated that baseline viral load was significantly higher in the patients infected with HCV-1a as compared to HCV-3a as well as in non-SVR patients compared with SVR patients (p=0.041) (Table 2). Previous reports have also confirmed these results (Martinez-Gomez et al., 2012; Domagalski et al., 2013).

In the patients of our study, the overall SVR rate was 56% (n=56). SVR rate was 18% in the HCV-1a patients and 38% in the HCV-3a patients. A recent work demonstrated that there were significantly releshionship between HCV genotype and SVR (p<0.001). A previous study on Iranian patients demonstrated that SVR rate in HCV-3 was more than that in patients with HCV-1 treated with pegIFN-α/RBV (Namazee et al., 2012).

Although an association between baseline viral load and IL28B rs12979860 polymorphism has been previously described (Ge et al., 2009; Rauch et al., 2010; Domagalski et al., 2013), in the present study, no relationship was observed between viral load and the IL28B polymorphisms (p=0.127).

Frequency of rs12979860 genotypes CC, CT, and TT in HCV genotype 1a was 10 (10%), 35 (35%), and 6 (6%), respectively and in HCV genotype 3a, it was 13 (13%), 31 (31%), and 5 (5%), respectively. The results of the present study indicate that the IL-28 rs12979860 CT genotype is the commonest genotype in CHC patients. These results were consistent (Zekri et al., 2014) and inconsistent with a number of studies (Sharafi et al., 2012).

Interestingly, various distributions of IL28B rs12979860 genotypes (protective rs12979860 CC genotype) among Caucasians, Asians, and Africans describe different rates of SVR in these populations. Previous studies have confirmed that rs12979860 CC allele has different frequencies in the worldwide population: CC allele’s frequency in African populations is 23% to 55%, in European population is 52% to 80%, in Southwest Asia is 75% to 98%, and in East Asia is 90% to 100% (Thomas et al., 2009).

Alternatively, various SVR rates might be in part described by distribution of different rs12979860 alleles in different HCV genotypes. In the current study, a lower frequency of CC genotype was found in the HCV-1a group in comparison with the HCV-3a (Table 3). In addition, it was demonstrated that the rs12979860 CC genotype was associated with SVR in HCV genotypes 1/3. Relationship between IL28B rs12979860 alleles and pegIFN-α/RBV treatment has been represented in different studies (Ge et al., 2009; Suppiah et al., 2009; Balagopal et al., 2010). The present study showed that CC allele in HCV genotype 1 and CC/CT alleles in HCV genotype 3 had an important role in infection control and SVR rate in CC group was higher than that in TT group among Iranian patients with chronic hepatitis C 1/3 (CHC-1/3). Sharafi et al. represented that CC and CT alleles in rs12979860, responded to treatment better than homozygous TT allele (Sharafi et al., 2011). Effect of rs12979860 polymorphism on the response to pegIFN-α/RBV treatment in patients infected with HCV-1 has been extensively demonstrated. Subjects that carry CC allele have SVR rates of more than 80%; so, this allele is considered to be favorable. By contrast, subjects with TT allele have SVR rates of less than 40%; so, it is considered unfavorable. It is clear which genotyping of the rs12979860 polymorphism is a strong predictor of the clinical outcome for HCV-1 patients (Balagopal et al., 2010), but also for HCV-3 to a lesser extent (Mangia et al., 2010; Sarrazin et al., 2011).

SVR rates in CC, CT, and TT (IL28B rs12979860) were 18%, 34%, and 4%, respectively. In current study, an association was found between SVR rates and IL28B polymorphisms. Understanding the associations between various IL28B polymorphisms and SVR after treatment with pegIFN-α/RBV is a major topic, because there is a debate over whether all untreated subjects should get triple therapy given the increased costs and possible adverse effects. In countries such as Iran, the analysis of offered strategies based on IL28B rs12979860 and SVR could be very useful in terms of cost-effectiveness. This analysis could also provide benefits related to adverse effects, treatment tolerance, and induction of viral drug resistance (Martinez-Gomez et al., 2012).

In conclusion, the HRM assay described herein was rapid, inexpensive, sensitive and accurate for detecting rs12979860 alleles in CHC patients. This method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be clinically beneficial in predicting treatment response in HCV genotype 1 and 3 infected patients. As also, it was demonstrated that CC and CT alleles in HCV-3a and CC allele in HCV-1a were significantly associated with response to pegIFN-α/RBV treatment. The present results may help identify subjects for whom the therapy might be successful.

Acknowledgements

We would like to thank all of the patients who participated in the study.

References

Afshar RM, Mollaie HR (2012). Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3657-61.

Akkarathamrongsin S, Thong VD, Payungporn S, et al (2014). IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol, 86, 1482-90.

Alavian SM, Tabatabaei SV, Keshvari M, et al (2010). Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a singlecentre study of 367 cases. Liver Int, 30, 1173-80.

Altuglu I, Soylor I, Ozacar T, et al (2008). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis, 12, 239-44.
Detection of rs12979860 IL28B Polymorphisms Involved in Response to Chronic Hepatitis C Treatment

Antaki N, Craxi A, Kamal S, et al (2010). Theneeglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int, 30, 342-55.

Asselah T, Bleche I, Paradis V, et al (2007). Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis, 27, 13-27.

Balagopal A, Thomas DL, Thio CL (2010). IL28B and the control of hepatitis C virus infection. Gastroenterology, 139, 1865-76.

Beinhardt S, Rutter K, Stuttermayer AF, Ferenci P (2013). Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis, 56, 118-22.

Chen X, Sullivan PF (2003). Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughpout. Pharmacogenomics J, 3, 77-96.

Dai CY, Huang JF, Hsieh MY, et al (2009). Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol, 50, 712-8.

Domagalski K, Pawłowska M, Tretya A, et al (2013). Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis, 32, 745-54.

Eslam M, Leung R, Romero-Gomez M, et al (2014). IFN3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol, 61, 235-41.

European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. From: http://www.easl.eu/_newsroom/latest-news/easl- recommendations-on-treatment-of-hepatitis-c-2014

Falleti E, Bitetto D, Fabris C, et al (2011). Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol, 31, 891-9.

Ge D, Fellay J, Thompson AJ, et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399-401

Ghany MG, Nelson DR, Strader DB, et al (2011). American association for study of liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-44.

Ghany MG, Strader DB, Thomas DL, Seeff LB (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49, 1335-74.

Grebely J, Petoumenos K, Hellard M, et al (2010). Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 52, 1216-24.

Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51.

Keyvani H, Alizadeh AH, Alavian SM, et al (2007). Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res, 37, 101-3.

Keyvani H, Fazalipour M, Monavari SH, et al (2012). Hepatitis C virus proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5931-49.

Mangia A, Thompson AJ, Santoro R, et al (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 139, 821-7.

Martínez-Gomez LE, Chavez-Tapia NC, Burgueño-García AI, et al (2012). IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol, 11, 876-81.

Melis R, Fauron C, McMillin G, et al (2011). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13, 446-51.

Moghaddam A, Melum E, Reinton N, et al (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology, 53, 746-54.

Namazzee N, Sali S, Asadi S, et al (2012). Real response to therapy in chronic hepatitis C virus patients: a study from Iran. Hepat Mon, 12, 6151.

Poon KS, Ho SS, Tang JW, et al (2012). Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28B genotyping. J Clin Microbiol, 50, 3353-5.

Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran: Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.

Rauch A, Kutalik Z, Descombes P, et al (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338-45.

Sajid A, Ayaz A, Raham Sh, et al. Genotyping of HCV RNA Reveals That 3a Is the Most Prevalent Genotype in Mardan, Pakistan. Advances in Virology, 2014, 1-5.

Samimi-Rad K, Nategh R, Malekzadeh R, et al (2004). Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol, 74, 246-52.

Sarrazin C, Susser S, Doehring A, et al (2011). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol, 54, 415-21.

Sharafi H, Pouryasin A, Alavian SM, et al (2012). Development and validation of a simple, rapid and inexpensive PCR-RFLP Method for genotyping of common IL28B polymorphisms: A useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon, 12, 190-5.

Shi X, Pan Y, Wang M, et al (2012). IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One, 7, 37054.

Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.

Suppiah V, Moldovan M, Ahlenstiel G, et al (2009). IL28B is associated with response to treatment for chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 41, 1100-4.

Thomas DL, Thio CL, Martin MP, et al (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461, 798-801.

Tsubota A, Kiyotaka F, Yoshihisa N, et al (2011). Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol, 17, 419-432.

Viazov S, Kuzin S, Paladi N, et al (1997). Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol, 53, 36-40.

Wohnsland A, Hofmann WP, Sarrazin C (2007). Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev, 20, 23-38.

Yang JD, Roberts LR (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol, 7, 448-58.

Zali MR, Mayumi M, Raouli M, et al (2000). Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J, 6, 372-7.

Zekri AR, Salama H, Medhat E, et al (2014). IL28B rs12979860
Gene polymorphism in Egyptian patients with chronic liver
disease infected with HCV. *Asian Pac J Cancer Prev*, 15,
7213-8.